VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
Title:
VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
Author:
Tutt, A.N.J. Garber, J. Gelber, R.D. Phillips, K-A. Eisen, A. Johannsson, O.T. Rastogi, P. Cui, K.Y. Im, S-A. Yerushalmi, R. Brufsky, A.M. Taboada, M. Rossi, G. Yothers, G. Singer, C. Fein, L.E. Loman, N. Cameron, D. Campbell, C. Geyer, C.E.